Novo Nordisk Q2 2026 Sales Up 7% but Full-Year Guidance Flags Decline

Novo Nordisk posted adjusted sales of DKK 78.49 billion and adjusted operating profit of DKK 33.39 billion for the second quarter of 2026. At constant exchange rates, sales grew 7% and operating profit rose 11% compared to the prior-year period.

Despite the quarterly growth, the company's outlook for the full year is cautious. It expects adjusted revenue growth to range between -6% and 0%, while adjusted EBIT growth is guided between -6% and 0% as well.

The weak guidance suggests that the strong second quarter may not carry through the remainder of the year, potentially due to headwinds or one-off factors. Investors will be watching for further details on the drivers behind the soft annual forecast.